Laurus Labs Limited (LAURUSLABS) - Total Liabilities

Latest as of September 2025: Rs44.82 Billion INR ≈ $484.68 Million USD

Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has total liabilities worth Rs44.82 Billion INR (≈ $484.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Laurus Labs Limited to see how much of total assets are deployed in long-term investments.

Laurus Labs Limited - Total Liabilities Trend (2013–2025)

This chart illustrates how Laurus Labs Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LAURUSLABS total asset value.

Laurus Labs Limited Competitors by Total Liabilities

The table below lists competitors of Laurus Labs Limited ranked by their total liabilities.

Company Country Total Liabilities
BJs Wholesale Club Holdings Inc
NYSE:BJ
USA $5.80 Billion
Hero MotoCorp Limited
NSE:HEROMOTOCO
India Rs116.42 Billion
Astra International Tbk
JK:ASII
Indonesia Rp209.04 Trillion
Guidewire Software Inc
NYSE:GWRE
USA $1.18 Billion
S-Oil Corp
KO:010950
Korea ₩17.67 Trillion
Fidelity National Financial Inc
NYSE:FNF
USA $105.72 Billion
MILLICOM INTL CELL. DL15
F:M4M1
Germany €13.63 Billion
Metso Oyj
HE:METSO
Finland €4.81 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Laurus Labs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Laurus Labs Limited net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.32 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.02 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.93 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.48 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Laurus Labs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Laurus Labs Limited (2013–2025)

The table below shows the annual total liabilities of Laurus Labs Limited from 2013 to 2025.

Year Total Liabilities Change
2025-03-31 Rs47.33 Billion
≈ $511.86 Million
+10.81%
2024-03-31 Rs42.71 Billion
≈ $461.94 Million
+18.27%
2023-03-31 Rs36.12 Billion
≈ $390.60 Million
+0.08%
2022-03-31 Rs36.09 Billion
≈ $390.30 Million
+14.57%
2021-03-31 Rs31.50 Billion
≈ $340.66 Million
+59.05%
2020-03-31 Rs19.81 Billion
≈ $214.19 Million
+11.72%
2019-03-31 Rs17.73 Billion
≈ $191.72 Million
+15.56%
2018-03-31 Rs15.34 Billion
≈ $165.91 Million
+15.96%
2017-03-31 Rs13.23 Billion
≈ $143.07 Million
-8.84%
2016-03-31 Rs14.51 Billion
≈ $156.94 Million
+29.36%
2015-03-31 Rs11.22 Billion
≈ $121.32 Million
+22.63%
2014-03-31 Rs9.15 Billion
≈ $98.93 Million
+105.95%
2013-03-31 Rs4.44 Billion
≈ $48.04 Million
--

About Laurus Labs Limited

NSE:LAURUSLABS India Drug Manufacturers - Specialty & Generic
Market Cap
$11.41 Billion
Rs1.05 Trillion INR
Market Cap Rank
#2024 Global
#78 in India
Share Price
Rs1954.00
Change (1 day)
+0.30%
52-Week Range
Rs832.30 - Rs1969.00
All Time High
Rs1969.00
About

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more